Daily Cardiology Research Analysis
Three randomized trials reshape contemporary cardiology: oral semaglutide reduced major adverse cardiovascular events in high‑risk type 2 diabetes, dapagliflozin lowered death or worsening heart failure after TAVI, and pulsed field ablation was noninferior (and modestly superior) to cryoballoon for paroxysmal atrial fibrillation with continuous rhythm monitoring. Together they expand cardiometabolic therapy into structural heart disease and advance safer, efficient EP ablation.
Summary
Three randomized trials reshape contemporary cardiology: oral semaglutide reduced major adverse cardiovascular events in high‑risk type 2 diabetes, dapagliflozin lowered death or worsening heart failure after TAVI, and pulsed field ablation was noninferior (and modestly superior) to cryoballoon for paroxysmal atrial fibrillation with continuous rhythm monitoring. Together they expand cardiometabolic therapy into structural heart disease and advance safer, efficient EP ablation.
Research Themes
- GLP-1 receptor agonists and cardiovascular outcomes
- SGLT2 inhibitors in structural heart disease (post-TAVI)
- Pulsed field ablation versus cryoablation in AF
Selected Articles
1. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
In the SOUL trial (n=9,650), oral semaglutide 14 mg daily reduced time-to-first MACE versus placebo over a median of 49.5 months (HR 0.86), with similar rates of serious adverse events and slightly more gastrointestinal events. Benefits were observed in patients with T2D and ASCVD and/or CKD.
Impact: This large, event-driven, double-blind RCT demonstrates cardiovascular efficacy of oral semaglutide, expanding GLP-1 benefits to an oral formulation with broad applicability.
Clinical Implications: Consider oral semaglutide for high-risk T2D patients with ASCVD/CKD to reduce MACE, especially when injectables are impractical; monitor for mild GI events. This supports incorporating oral GLP-1RA into cardiometabolic risk reduction strategies.
Key Findings
- Primary MACE reduced with oral semaglutide vs placebo (HR 0.86; 95% CI 0.77–0.96).
- Serious adverse events were similar (47.9% vs 50.3%); gastrointestinal disorders slightly higher with semaglutide (5.0% vs 4.4%).
- Efficacy observed in a high-risk population with ASCVD and/or CKD over a long median follow-up of 49.5 months.
Methodological Strengths
- Large, double-blind, placebo-controlled, event-driven design
- Adequate follow-up (median ~4 years) with prespecified endpoints and trial registration
Limitations
- Confirmatory secondary outcomes were not significantly different
- Generalizability limited to ≥50-year-old T2D patients with ASCVD/CKD and max 14 mg dose
Future Directions: Define responders, evaluate earlier use and combination with SGLT2i, and assess cost-effectiveness and adherence advantages of oral GLP-1RA in routine cardiometabolic care.
BACKGROUND: The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both is needed. METHODS: In this double-blind, placebo-controlled, event-driven, superiority trial, we randomly assigned participants who were 50 years of age or older, had type 2 diabetes with a glycated hemoglobin level of 6.5 to 10.0%, and had known atherosclerotic cardiovascular disease, chronic kidney disease, or both to receive either once-daily oral semaglutide (maximal dose, 14 mg) or placebo, in addition to standard care. The primary outcome was major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke), assessed in a time-to-first-event analysis. The confirmatory secondary outcomes included major kidney disease events (a five-point composite outcome). RESULTS: Among the 9650 participants who had undergone randomization, the mean (±SD) follow-up was 47.5±10.9 months, and the median follow-up was 49.5 months. A primary-outcome event occurred in 579 of the 4825 participants (12.0%; incidence, 3.1 events per 100 person-years) in the oral semaglutide group, as compared with 668 of the 4825 participants (13.8%; incidence, 3.7 events per 100 person-years) in the placebo group (hazard ratio, 0.86; 95% confidence interval, 0.77 to 0.96; P = 0.006). The results for the confirmatory secondary outcomes did not differ significantly between the two groups. The incidence of serious adverse events was 47.9% in the oral semaglutide group and 50.3% in the placebo group; the incidence of gastrointestinal disorders was 5.0% and 4.4%, respectively. CONCLUSIONS: Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events. (Funded by Novo Nordisk; SOUL ClinicalTrials.gov number, NCT03914326.).
2. Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation.
In a randomized trial with continuous rhythm monitoring, PFA showed a lower 1-year atrial arrhythmia recurrence (37.1%) than cryoballoon (50.7%), meeting noninferiority and achieving marginal superiority, with low and comparable complication rates (1.0% vs 1.9%).
Impact: Provides high-quality, head-to-head evidence that supports PFA as an effective and safe first-line energy source for PVI, likely accelerating adoption and guideline updates in EP.
Clinical Implications: For symptomatic paroxysmal AF, PFA is a compelling alternative to cryoballoon ablation with lower recurrence under continuous monitoring and similar safety; centers may prioritize PFA where available.
Key Findings
- Primary endpoint met for noninferiority with a −13.6 percentage-point difference in recurrence (P<0.001) and achieved superiority (P=0.046).
- Atrial arrhythmia recurrence: 37.1% (PFA) vs 50.7% (cryo) from day 91 to 365.
- Procedure-related complications were low and comparable (1.0% vs 1.9%).
Methodological Strengths
- Randomized head-to-head comparison with continuous implantable monitor follow-up
- Clear, patient-centered primary endpoint with prespecified noninferiority and superiority framework
Limitations
- Single-country trial with modest sample size (n=210) and 12-month horizon
- Noninferiority margin (20 percentage points) is relatively wide
Future Directions: Larger, multicountry trials in persistent AF, long-term lesion durability, and real-world safety profiling across diverse anatomies and comorbidities.
BACKGROUND: Pulmonary-vein isolation is an effective treatment for paroxysmal atrial fibrillation. Pulsed field ablation (PFA) is a nonthermal ablation method with few adverse effects beyond the myocardium. Data are lacking on outcomes after PFA as compared with cryoballoon ablation as assessed with continuous rhythm monitoring. METHODS: In this randomized noninferiority trial in Switzerland, we randomly assigned patients with symptomatic paroxysmal atrial fibrillation in a 1:1 ratio to undergo PFA or cryoablation. All the patients received an implantable cardiac monitor to detect atrial tachyarrhythmias. The primary end point was the first recurrence of an atrial tachyarrhythmia between day 91 and day 365 after ablation. We assessed noninferiority using a margin of 20 percentage points for the difference in the cumulative incidence of recurrence. The safety end point was a composite of procedure-related complications. RESULTS: A total of 105 patients were assigned to undergo PFA, and 105 were assigned to undergo cryoablation. A recurrence of atrial tachyarrhythmia was observed between day 91 and day 365 in 39 patients in the PFA group and in 53 patients in the cryoablation group (Kaplan-Meier cumulative incidence, 37.1% and 50.7%, respectively; between-group difference, -13.6 percentage points; 95% confidence interval, -26.9 to -0.3; P<0.001 for noninferiority, P = 0.046 for superiority). The safety end point occurred in 1 patient (1.0%) with PFA and in 2 patients (1.9%) with cryoablation. CONCLUSIONS: Among patients with symptomatic paroxysmal atrial fibrillation, PFA was noninferior to cryoballoon ablation with respect to the incidence of a first recurrence of atrial tachyarrhythmia, as assessed by continuous rhythm monitoring. (Funded by Inselspital and others; SINGLE SHOT CHAMPION ClinicalTrials.gov number, NCT05534581.).
3. Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation.
In high-risk TAVI recipients with prior heart failure, dapagliflozin 10 mg daily reduced the 1-year composite of all-cause death or worsening HF (HR 0.72), driven by fewer HF events (subhazard ratio 0.63), with neutral all-cause mortality and higher rates of genital infections and hypotension.
Impact: First randomized evidence that SGLT2 inhibition benefits a post-TAVI population, extending cardiorenal therapeutics into structural heart disease care pathways.
Clinical Implications: For older TAVI patients with HF risk, initiate dapagliflozin to reduce HF events post-procedure, with monitoring for genital infections and hypotension. Integrate SGLT2i into post-TAVI HF prevention protocols.
Key Findings
- Primary composite (all-cause death or worsening HF) reduced with dapagliflozin at 1 year (15.0% vs 20.1%; HR 0.72; 95% CI 0.55–0.95; P=0.02).
- Reduction mainly driven by fewer worsening HF events (9.4% vs 14.4%; subhazard ratio 0.63).
- All-cause mortality neutral (HR 0.87), with higher genital infections and hypotension in the dapagliflozin group.
Methodological Strengths
- Randomized controlled design targeting an under-studied post-TAVI population
- Clinically meaningful, adjudicated composite outcome with adequate sample size (~1,222 analyzed)
Limitations
- Single-country trial; external validity across diverse TAVI practices uncertain
- Increased adverse events (genital infections, hypotension) require careful monitoring
Future Directions: Assess optimal timing and duration post-TAVI, explore synergy with GLP-1RA, and evaluate cost-effectiveness and frailty-specific outcomes.
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However, most patients with valvular heart disease, including those undergoing transcatheter aortic-valve implantation (TAVI), have been excluded from randomized trials. METHODS: We conducted this randomized, controlled trial in Spain to evaluate the efficacy of dapagliflozin (at a dose of 10 mg once daily) as compared with standard care alone in patients with aortic stenosis who were undergoing TAVI. All the patients had a history of heart failure plus at least one of the following: renal insufficiency, diabetes, or left ventricular systolic dysfunction. The primary outcome was a composite of death from any cause or worsening of heart failure, defined as hospitalization or an urgent visit, at 1 year of follow-up. RESULTS: A total of 620 patients were randomly assigned to receive dapagliflozin and 637 to receive standard care alone after TAVI; after exclusions, a total of 1222 patients were included in the primary analysis. A primary-outcome event occurred in 91 patients (15.0%) in the dapagliflozin group and in 124 patients (20.1%) in the standard-care group (hazard ratio, 0.72; 95% confidence interval [CI], 0.55 to 0.95; P = 0.02). Death from any cause occurred in 47 patients (7.8%) in the dapagliflozin group and in 55 (8.9%) in the standard-care group (hazard ratio, 0.87; 95% CI, 0.59 to 1.28). Worsening of heart failure occurred in 9.4% and 14.4% of the patients, respectively (subhazard ratio, 0.63; 95% CI, 0.45 to 0.88). Genital infection and hypotension were significantly more common in the dapagliflozin group. CONCLUSIONS: Among older adults with aortic stenosis undergoing TAVI who were at high risk for heart-failure events, dapagliflozin resulted in a significantly lower incidence of death from any cause or worsening of heart failure than standard care alone. (Funded by Instituto de Salud Carlos III and others; ClinicalTrials.gov number, NCT04696185.).